CLEAR Outcomes Company Update Call: Detailed Results Discussion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC
February 24, 2023 11:34 AM ESTJefferies upgraded Esperion Therapeutics (NASDAQ: ESPR) to a Buy rating (From Hold) and doubled the price target on the stock to $6.00 (From $12.00) following incrementally positive management comments heading into the CLEAR CV outcomes data at ACC on March 4th.
Jefferies analysts are confident ESPR should meet or beat the Street's 15% cardiovascular benefit "bar," but even... More



